Technology Search

Order Results:

Your search returned '115' results

  • Dapagliflozin for type 2 diabetes

    Agency: NHSC

    Name: Dapagliflozin, BMS 5121-148

    Technology Type: Drug

    Patient Indications: Type 2 diabetes mellitus: add-on therapy with metformin, insulin, a sulphonylurea or a thiazolidinedione.

    Entered On: January 29 2010

  • Rivaroxaban (Xarelto) for venous thromboembolism

    Agency: NHSC

    Name: Rivaroxaban (Xarelto)

    Technology Type: Drug

    Patient Indications: • Venous thromboembolism (VTE) – treatment and long term secondary prevention of VTE.

    Entered On: February 1 2010

  • Lapatinib plus paclitaxel for metastatic breast cancer - first line

    Agency: NHSC

    Name: Lapatinib (Tyverb(TM), GW-572016)

    Technology Type: Drug

    Patient Indications: Breast cancer: metastatic, HER-2 (ErbB2) positive - first line; in combination with paclitaxel.

    Entered On: February 1 2010

  • Asenapine (Sycrest) for manic episodes associated with bipolar l disorder

    Agency: NHSC

    Name: Asenapine (Sycrest(TM), Org-5222)

    Technology Type: Drug

    Patient Indications: Bipolar 1 disorder: manic episodes - adults; first or second line; monotherapy or in combination with mood stabilisers.

    Entered On: February 1 2010

  • Ustekinumab for psoriatic arthritis – second line after disease modifying anti – rheumatic drugs

    Agency: NHSC

    Name: Ustekinumab (Stelara (TM), CNTO - 1275, CNTO 1275)

    Technology Type: Drug

    Patient Indications: Psoriatic arthritis (PsA) – adults; second line after failure of disease modifying anti-rheumatic drugs (DMARDs).

    Entered On: February 1 2010

  • Sunitinib for advanced and/or metastatic pancreatic islet cell tumours

    Agency: NHSC

    Name: Sunitinib

    Technology Type: Drug

    Patient Indications: • Pancreatic islet cell tumours: well differentiated advanced and/or metastatic not, amenable to treatment with curative intent.

    Entered On: February 2 2010

  • Asenapine (Sycrest) for schizophrenia

    Agency: NHSC

    Name: Asenapine (Sycrest(TM), Org-5222)

    Technology Type: Drug

    Patient Indications: Schizophrenia: acute and maintenance treatment.

    Entered On: February 2 2010

  • Laparoscopic helium plasma coagulation (HELICA) for endemetriosis

    Agency: AETSA

    Name: Laparoscopic helium plasma coagulation (HELICA)

    Technology Type: Procedure

    Patient Indications: Endometriosis stages I to III (minimal to moderate).

    Entered On: February 11 2010

  • Intelence – Etravirine (TMC125)

    Agency: DMTP

    Name: Intelence – Etravirine (TMC125)

    Technology Type: Drug

    Patient Indications: For the treatment of HIV1 patients resistant to NNRTI. Mechanism of action is inhibiting the enzyme transcriptase.

    Entered On: February 23 2010

  • Vorinostat for multiple myeloma

    Agency: NHSC

    Name: MK 0683, Zolinza

    Technology Type: Drug

    Patient Indications: Multiple myeloma: refractory – second and/or third line; in combination with bortezomib.

    Entered On: February 25 2010

  • Accuvein AV300 for locating peripheral veins for venipuncture

    Agency: NHSC

    Name: Accuvein AV300

    Technology Type: Device

    Patient Indications: Adults and children requiring venipuncture.

    Entered On: February 26 2010

  • VIDION beta radiation brachytherapy system for neovascular age-related macular degeneration

    Agency: NHSC

    Name: VIDION

    Technology Type: Procedure Device

    Patient Indications: Neovascular (wet) age-related macular degeneration (AMD) in patients eligible for anti-VEGF intraocular injections such as, ranibizumab and bevacizumab.

    Entered On: February 26 2010

  • Jurnista – Hydromorphone for severe pain

    Agency: DMTP

    Name: Jurnista – Hydromorphone for severe pain

    Technology Type: Drug

    Patient Indications: Patient with severe chronic pain, cancer-related & non-cancer pain.

    Entered On: March 1 2010

  • Gefitinib (Iressa®) for the first-line treatment of non-small cell lung cancer

    Agency: LBI -HTA

    Name: Gefitinib, Iressa®

    Technology Type: Drug

    Patient Indications: as first-line therapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with activating mutations of EGFR TK.

    Entered On: March 9 2010

  • Trabectedin for second-line recurrent platinum-sensitive ovarian cancer

    Agency: LBI -HTA

    Name: Trabectedin, Yondelis ®

    Technology Type: Drug

    Patient Indications: Trabectedin is indicated for the treatment of patients (pts) with advanced, recurrent/relapsed platinum-sensitive ovarian cancer in combination with pegylated liposomal doxorubicin (PLD).

    Entered On: March 16 2010

  • CONESTAT-ALFA for acute attacks of hereditary angioedema

    Agency: IHSP

    Name: CONESTAT-ALFA

    Technology Type: Drug

    Patient Indications: Acute attacks of HEA

    Entered On: March 24 2010

  • TICAGRELOR for treatment of acute coronary syndromes

    Agency: IHSP

    Name: Brilinta (ticagrelor)

    Technology Type: Drug

    Patient Indications: Acute Coronary Syndromes (ACS)

    Entered On: March 24 2010

  • Minimally invasive application of Botulinum toxin type A for the treatment of idiopathic rhinitis

    Agency: AETS

    Name: Botulinum toxin type A (BTA). Botox®

    Technology Type: Procedure

    Patient Indications: Patients with idiopathic rhinitis (IR), also known as vasomotor rhinitis or intrinsic rhinitis.

    Entered On: March 25 2010

  • Platelia Apsergillus Antigen EIA test for Invasive Aspergillosis in high risk patients

    Agency: NHSC

    Name: Platelia Apsergillus Antigen enzyme immunoassay (EIA) test

    Technology Type: Diagnostics

    Patient Indications: Neutropenic patients, especially those at high risk for Invasive Aspergillosis (IA), e.g. transplant patients and those receiving chemotherapy for haematological malignancies or lymphoma.

    Entered On: March 25 2010

  • BCtect for the early detection of breast cancer

    Agency: NHSC

    Name: BCtect

    Technology Type: Diagnostics

    Patient Indications: Women undergoing screening for breast cancer, especially pre-menopausal women with a medium or high risk of developing breast cancer.

    Entered On: March 25 2010

  • DoseCheck 5-FU PCM Assay for pharmacokinetic-guided dose management of cancer chemotherapy

    Agency: NHSC

    Name: DoseCheck 5-FU Personalised Chemotherapy Management (PCM) Assay

    Technology Type: Other, not otherwise specified Diagnostics

    Patient Indications: Cancer patients receiving chemotherapy in which 5-FU is administered by continuous infusion.

    Entered On: April 1 2010

  • Copeptin assay to rule out acute myocardial infarction in patients with acute chest pain

    Agency: NHSC

    Name: Copeptin assay

    Technology Type: Diagnostics

    Patient Indications: Acute chest pain of suspected cardiac origin in patients attending Accident and Emergency (A&E), especially those aged over 30 years.

    Entered On: April 1 2010

  • Somatom Definition Flash computed tomography (CT) scanner for cardiac and other imaging

    Agency: NHSC

    Name: SOMATOM Definition Flash computed tomography (CT) scanner

    Technology Type: Procedure Diagnostics

    Patient Indications: (1) Patients requiring diagnostic CT imaging, especially: • Paediatric patients and adult patients for whom breath hold is difficult or impossible. • Patients who would normally require beta-blockers to slow the heart down to obtain images of a sufficiently high quality. • Patients with chest pain requiring ‘triple rule out’ of pulmonary embolism, aortic dissection and coronary occlusion. • Patients requiring brain perfusion studies. • Patients requiring disease staging for cancer. • Severely traumatised or unconscious patients. (2) Patients requiring assessment or diagnosis for cardiovascular conditions, especially: • Patients requiring diagnostic coronary examination, currently performed by invasive coronary catheterisation. • Patients requiring cardiac stress perfusion, currently undertaken by nuclear medicine imaging. According to the company this is the first CT scanner capable of cardiac stress perfusion, which may provide a faster and cheaper alternative to single photon emission computed tomography (SPECT) imaging.

    Entered On: April 1 2010

  • Xarelto Rivaroxaban - prevention of venous thromboembolism after surgery

    Agency: DMTP

    Name: Xarelto Rivaroxaban - prevention of venous thromboembolism after surgery

    Technology Type: Drug

    Patient Indications: For prevention of venous thromboembolism in adult patients undergoing elective hip or knee replacement surgery – 10 mg daily from day 1 (6 hours post-operation) continuing for 5 weeks for hip or femoral surgery and 2 weeks for knee surgery post-operation).

    Entered On: April 6 2010

  • Isoflow infusion catheter for targeted drug delivery to tumours

    Agency: NHSC

    Name: Isoflow infusion catheter

    Technology Type: Device

    Patient Indications: Cancer - primary or recurrent, locally advanced solid tumours. Isoflow may provide an additional treatment option for patients who are not surgical candidates or who have already received treatments such as, RF ablation, chemoembolisation, radiation and systemic chemotherapy. It is not intended for use in coronary vessels.

    Entered On: April 9 2010